BioSpace News Archive

Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that it will host a conference call and live audio webcast on May 8, 2020 at 10:00 a.m. EDT to report its first quarter 2020 financial results and provide an update on its b

-- Completed rolling NDA submission to FDA for setmelanotide in POMC and LEPR deficiency obesities; on track to submit MAA to EMA in the second quarter of 2020 – -- Received Orphan Drug Designation from FDA for setmelanotide for the treatment of Alström syndrome -- -- Continues to expect topline data from pivotal Phase 3 trial of setmelanotide in Bardet-Biedl and Alström syndromes in fourth quarter of 2020 or early in the first quarter of 2021 -- BOSTON, May 04, 2020 (GLOBE NEWSWIRE)

Hikma Pharmaceuticals PLC announces that its venture capital arm, Hikma Ventures has invested in Altoida, Inc. following the company’s $6.3 million Series A round in 2019..

As the current COVID-19 health crisis demonstrates, medical laboratories and the pathologists who oversee them to develop and conduct tests are relied upon to steer many of the health care decisions for the ultimate wellbeing of patients everywhere.

Appili Therapeutics Inc. (the “Company” or “Appili”), a biopharmaceutical company focused on anti-infective drug development, announced today that Appili’s CEO Dr. Armand Balboni will be a panelist at the upcoming “Infectious Disease Virtual Conference” presented by Maxim Group. Dr. Balboni will be discussing Appili’s ATI-2307 program, a novel antifungal for resistant infections that the Company acquired from FUJIFI

Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced that Clive Richardson, Chief Executive Officer, will participate and host investor meetings during the STRH Life Sciences Virtual Meeting Series. SunTrust Robinson Humphrey (STRH) Life Sciences Vir

Sequana Medical NV, an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, announces the appointment of Oliver Gödje, MD, PhD, as Chief Medical Officer, with immediate effect.

Galecto, Inc. announced new data describing the preclinical and clinical evidence for anti-fibrotic activity of its lead compound GB0139, in an abstract for the Experimental Biology 2020 conference.

Ipsen, a global specialty-driven biopharmaceutical group, IRICoR, a pan-Canadian research commercialization center focused on drug discovery, and Université de Montréal, announced they entered into an option agreement by which Ipsen would acquire an exclusive license for the worldwide rights to a high-value oncology program.

Pharmaceutics International, Inc., a US-based Contract Development and Manufacturing Organization announced it has won the 2020 CDMO Leadership Award and was named the Most Innovative Company in Dosage Solutions by Global Health & Pharma Magazine.